ArticleJournal of clinical laboratory analysis2023
C-reactive protein/albumin ratio and IL-6 are associated with disease activity in patients with ulcerative colitis.
Article in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and network meta-analysis of integrated traditional Chinese and conventional medicine for ulcerative colitis.Frontiers in pharmacology · 2026Pooled it
- Diagnostic and prognostic utility of SIRI and CAR in necrotizing fasciitis: a retrospective cohort study on disease severity and clinical outcomes.European journal of medical research · 2026Article
- From blood to bowel: correlating serological markers with mucosal healing and inflammation in patients with inflammatory bowel disease.Frontiers in immunology · 2026Article
- Correlation between inflammatory markers and disease severity in ulcerative colitis.World journal of gastrointestinal surgery · 2025Article
- Enterogenic dementia: defining the gut-brain axis and the role of inflammatory bowel disease in cognitive impairment.Inflammopharmacology · 2025Review
- Prediction of vedolizumab efficacy in ulcerative colitis: a nomogram incorporating pathological feature and serological marker.Clinical and experimental medicine · 2025Article
- The MicroRNA miR-223 Constrains Colitis-associated Tumorigenesis by Limiting Myeloid Cell Infiltration and Chemokine Expression.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure.Journal of clinical medicine · 2024Article
- Fibrinogen, FDP and D-Dimer as Potential Biomarkers for Disease Severity in Ulcerative Colitis: A Retrospective Study.International journal of general medicine · 2024Article
- Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study.Frontiers in medicine · 2024Article
- High C-reactive protein-to-albumin ratio levels are associated with osteoporosis in patients with primary biliary cholangitis.Frontiers in endocrinology · 2024Article
- C-reactive protein/albumin ratio and IL-6 are associated with disease activity in patients with ulcerative colitis.Journal of clinical laboratory analysis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCytokines are key mediators of the inflammation in ulcerative colitis (UC); there are inconsistent data on cytokines profile in patients with UC. C-reactive protein/albumin ratio (CRP/ALB) has also been found as an inflammatory indicator. However, the role of CRP/ALB in UC remains unclear. We aimed to evaluate the CRP/ALB ratio and cytokines profile in patients with UC. We further explore the association between CRP/ALB and inflammatory markers, such as erythrocyte sedimentation rate (ESR), fecal calprotectin (FC) and cytokines.
methodsOne hundred thirty UC patients and 65 controls were included in the study. Clinical and laboratory findings were retrospectively reviewed; differences in variables between two groups were examined using the Mann-Whitney U-test. The association between CRP/ALB, cytokines, and clinical parameters was determined by Spearman's correlation test.
resultsCRP/ALB levels were significantly elevated in active UC patients. The optimal cutoff level of the CRP/ALB was 0.083. The patients with active UC had a median interleukin-6 (IL-6) level of 7.715 pg/ml (interquartile ranges, IQR 3.475-14.63), which was significantly higher than those in remission (2.95 pg/ml, IQR 2.17-5.44) (p < 0.001). Positive correlations between CRP/ALB and inflammatory markers were also observed.
conclusionsOur results suggest that CRP/ALB and IL-6 could be potential biomarkers for assessment of clinical activity in Chinese patients with UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.